Apolipoprotein AI mimetic peptides: Possible new agents for the treatment of atherosclerosis

Current Opinion in Investigational Drugs

Volumn 8, Issue 3, 2007, Pages 201-212

  Sethi, Amar A ^a   Amar, Marcelo ^a   Shamburek, Robert D ^a   Remaley, Alan T ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Acute HDL therapy; Apolipoprotein AI; Atherosclerosis; Coronary heart disease; HDL; LDL; Mimetic peptide

Indexed keywords

ACETYLASPARTYLTRYPTOPHYLLEUCYLLYSYLALANYLPHENYLALANYL TYROSYLASPARTYLLYSYLVALYLPHENYLALANYLGLUTAMYLLYSYLPHENYLALANYLLYSYL GLUTAMYLPHENYLALANYLPHENYLALANINAMIDE; ACETYLASPARTYLTRYPTOPHYLLEUCYLLYSYLALANYLPHENYLALANYLTYROSYL ASPARTYLLYSYLVALYLALANYLGLUTAMYLLYSYLLEUCYLLYSYLGLUTAMYLALANYLPHENYLALANINAMIDE; ACETYLASPARTYLTRYPTOPHYLPHENYLALANYLLYSYLALANYLPHENYLALANYL TYROSYLASPARTYLLYSYLVALYLALANYLGLUTAMYLLYSYLPHENYLALANYLLYSYL GLUTAMYLALANYLPHENYLALANINAMIDE; ACETYLGLYCYLGLUTAMYLGLUTAMYLMETHIONYLARGINYLASPARTYL ARGINYLALANYLARGINYLALANYLHISTIDYLVALYLASPARTYLALANYLLEUCYL ARGINYLTHREONYLHISTIDINAMIDE; ACETYLLEUCYLARGINYLLYSYLLEUCYLARGINYLLYSYLARGINYLLEUCYLLEUCYL ARGINYLPROLYLASPARTYLTRYPTOPHYLLEUCYLLYSYLALANYLPHENYLALANYL TYROSYLASPARTYLLYSYLVALYLALANYLGLUTAMYLLYSYLLEUCYLLYSYL GLUTAMYLALANYLPHENYLALANINAMIDE; ACETYLLEUCYLVALYLGLYCYLARGINYLGLUTAMINYLLEUCYLGLUTAMYL GLUTAMYLPHENYLALANYLLEUCINAMIDE; ACETYLPHENYLALANYLALANYLGLUTAMYLLYSYLPHENYLALANYLLYSYL GLUTAMYLALANYLVALYLLYSYLASPARTYLTYROSYLPHENYLALANYLALANYLLYSYLPHENYL ALANYLTRYPTOPHYLASPARTYLAMIDE; ACETYLSERYLASPARTYLGLUTAMYLLEUCYLARGINYLGLUTAMINYL ARGINYLLEUCYLALANYLALANYLARGINYLLEUCYLGLUTAMYLALANYLLEUCYLLYSYL GLUTAMYLASPARAGINAMIDE; APOLIPOPROTEIN A1; ASPARTYLHISTIDYLTRYPTOPHYLPHENYLALANYLLYSYLALANYLPHENYL ALANYLTYROSYLASPARTYLLYSYLVALYLCYSTEINYLGLUTAMYLLYSYLPHENYLALANYLLYSYL GLUTAMYLPHENYLALANINE; GLUTAMYLLYSYLISOLEUCYLSERYLASPARTYLALANYLARGINYL GLUTAMYLSERYLPHENYLALANYLGLUTAMINYLGLUTAMYLPHENYLALANYLPHENYL ALANYLGLYCYLARGINYLGLYCYLHISTIDYLGLUTAMYLASPARTYLTHREONYL METHIONYLALANYLASPARTYLGLUTAMINYLGLUTAMYLALANYLASPARAGINYLARGINYLHISTIDINE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; METHIONYLLYSYLLEUCYLLEUCYLTHREONYLSERYLLEUCYLVALYLPHENYLALANYL CYSTEINYLSERYLLEUCYLLEUCYLLEUCYLGLYCYLVALYLCYSTEINYLHISTIDYLGLYCYLGLYCINE; PEPTIDE DERIVATIVE; PROLYLVALYLLEUCYLASPARTYLLEUCYLPHENYLALANYLARGINYL GLUTAMYLLEUCYLLEUCYLASPARAGINYLGLUTAMYLLEUCYLLEUCYL GLUTAMYLALANYLLEUCYLLYSYLGLUTAMINYLLYSYLLEUCYLLYSINE; RECOMBINANT APOLIPOPROTEIN A1; RECOMBINANT HIGH DENSITY LIPOPROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; C57BL 6 MOUSE; CLINICAL TRIAL; DRUG MECHANISM; DRUG TARGETING; HEART PROTECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIC HEART DISEASE; KNOCKOUT MOUSE; LIPOPROTEIN METABOLISM; NONHUMAN; REVIEW;

ANIMALS; APOLIPOPROTEIN A-I; ARTERIOSCLEROSIS; CHEMISTRY, PHARMACEUTICAL; HUMANS; HYDROPHOBICITY; MODELS, CHEMICAL; PEPTIDES;

EID: 33947307937     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Barr DP, Russ EM, Eder HA: Protein-lipid relationships in human plasma. II. In atherosclerosis and related conditions. Am J Med (1951) 11(4):480-493.
2. Sacks FM: The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: Evidence from large-scale statin and fibrate trials. Am J Cardiol (2001) 88(12A):14N-18N.
3. van der Velde AE, Groen AK: Shifting gears: Liver SR-BI drives reverse cholesterol transport in macrophages. J Clin Invest (2005) 115(10):2699-2701.
4. Nofer JR, Remaley AT: Tangier disease: Still more questions than answers. Cell Mol Life Sci (2005) 62(19-20):2150-2160.
5. Dean M: The genetics of ATP-binding cassette transporters. Methods Enzymol (2005) 400:409-429.
6. Brewer HB Jr, Remaley AT, Neufeld EB, Basso F, Joyce C: Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler Thromb Vasc Biol (2004) 24(10):1755- 1760.
7. Badimon JJ, Badimon L, Fuster V: Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest (1990) 85(4):1234-1241.
8. Newton RS, Krause BR: HDL therapy for the acute treatment of atherosclerosis. Atherosclerosis Suppl (2002) 3(4):31-38.
9. Milano-phospholipid complexes.
10. Mineo C, Deguchi H, Griffin JH, Shaul PW: Endothelial and antithrombotic actions of HDL. Circ Res (2006) 98(11):1352- 1364.
11. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM: Antiinflammatory properties of HDL. Circ Res (2004) 95(8):764-772. •• This paper highlights recent advances in HDL biology by summarizing findings from cell culture, animal models and studies in humans with particular emphasis on HDL's capacity to modify endothelial NO synthase expression and activity. The production of the atheroprotective signaling molecule NO is also discussed.
12. Yancey PG, Bortnick AE, Kellner-Weibel G, de la Llera-Moya M, Phillips MC, Rothblat GH: Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol (2003) 23(5):712-719.
13. Basso F, Freeman L, Knapper CL, Remaley A, Stonik J, Neufeld EB, Tansey T, Amar MJ, Fruchart-Najib J, Duverger N, Santamarina-Fojo S, Brewer HB Jr: Role of the hepatic ABCA1 transporter in modulating intrahepatic cholesterol and plasma HDL cholesterol concentrations. J Lipid Res (2003) 44(2):296-302.
14. Singaraja RR, Bocher V, James ER, Clee SM, Zhang LH, Leavitt BR, Tan B, Brooks-Wilson A, Kwok A, Bissada N, Yang YZ et al: Human ABCA1 BAC transgenic mice show increased high density lipoprotein cholesterol and apoAI-dependent efflux stimulated by an internal promoter containing liver X receptor response elements in intron 1. J Biol Chem (2001) 276(36):33969-33979.
15. Lee JY, Timmins JM, Mulya A, Smith TL, Zhu Y, Rubin EM, Chisholm JW, Colvin PL, Parks JS: HDLs in apoA-I transgenic ABCA1 knockout mice are remodeled normally in plasma but are hypercatabolized by the kidney. J Lipid Res (2005) 46(10):2233-2245.
16. Brunham LR, Kruit JK, Iqbal J, Fievet C, Timmins JM, Pape TD, Coburn BA, Bissada N, Staels B, Groen AK, Hussain MM et al: Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest (2006) 116(4):1052-1062.
17. Lerch PG, Spycher MO, Doran JE: Reconstituted high density lipoprotein (rHDL) modulates platelet activity in vitro and ex vivo. Thromb Haemost (1998) 80(2):316-320.
18. Fleisher LN, Tall AR, Witte LD, Miller RW, Cannon PJ: Stimulation of arterial endothelial cell prostacyclin synthesis by high density lipoproteins. J Biol Chem (1982) 257(12):6653-6655.
19. Norata GD, Banfi C, Pirillo A, Tremoli E, Hamsten A, Catapano AL, Eriksson P: Oxidised-HDL3 induces the expression of PAI-1 in human endothelial cells. Role of p38MAPK activation and mRNA stabilization. Br J Haematol (2004) 127(1):97-104.
20. Navab M, Anantharamaiah GM, Fogelman AM: The role of high-density lipoprotein in inflammation. Trends Cardiovasc Med (2005) 15(4):158-161.
21. Ansell BJ, Watson KE, Fogelman AM, Navab M, Fonarow GC: High-density lipoprotein function recent advances. J Am Coll Cardiol (2005) 46(10):1792-1798.
22. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Hama S, Hough G, Bachini E, Grijalva VR, Wagner AC, Shaposhnik Z, Fogelman AM: The double jeopardy of HDL. Ann Med (2005) 37(3):173-178. • This review summarizes the anti-inflammatory and pro-inflammatory role of HDL in different mice strains.
23. Barter PJ, Rye KA: Relationship between the concentration and antiatherogenic activity of high-density lipoproteins. Curr Opin Lipidol (2006) 17(4):399-403.
24. Nofer JR, Remaley AT, Feuerborn R, Wolinnska I, Engel T, von Eckardstein A, Assmann G: Apolipoprotein A-I activates Cdc42 signaling through the ABCA1 transporter. J Lipid Res (2006) 47(4):794-803.
25. Nofer JR, van der Giet M, Tolle M, Wolinska I, von Wnuck Lipinski K, Baba HA, Tietge UJ, Godecke A, Ishii I, Kleuser B, Schafers M et al: HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest (2004) 113(4):569-581.
26. Rohrer L, Cavelier C, Fuchs S, Schluter MA, Volker W, von Eckardstein A: Binding, internalization and transport of apolipoprotein A-I by vascular endothelial cells. Biochim Biophys Acta (2006) 1761(2):186- 194.
27. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, Vahabzadeh K, Hama S, Hough G, Kamranpour N, Berliner JA et al: The oxidation hypothesis of atherogenesis: The role of oxidized phospholipids and HDL. J Lipid Res (2004) 45(6):993-1007. •• A comprehensive review of the oxidation hypothesis, with an emphasis on oxidized phospholipids and HDL.
28. Ohashi R, Mu H, Wang X, Yao Q, Chen C: Reverse cholesterol transport and cholesterol efflux in atherosclerosis. QJM Int J Med (2005) 98(12):845-856.
29. Trogan E, Feig JE, Dogan S, Rothblat GH, Angeli V, Tacke F, Randolph GJ, Fisher EA: Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci USA (2006) 103(10):3781-3786.
30. Schwartz CC, VandenBroek JM, Cooper PS: Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J Lipid Res (2004) 45(9):1594-1607.
31. Nanjee MN, Crouse JR, King JM, Hovorka R, Rees SE, Carson ER, Morgenthaler JJ, Lerch P, Miller NE: Effects of intravenous infusion of lipid-free apo A-I in humans. Arterioscler Thromb Vasc Biol (1996) 16(9):1203-1214.
32. Lerch PG, Fortsch V, Hodler G, Bolli R: Production and characterization of a reconstituted high density lipoprotein for therapeutic applications. Vox Sang (1996) 71(3):155-164.
33. Nanjee MN, Doran JE, Lerch PG, Miller NE: Acute effects of intravenous infusion of apoA1/phosphatidylcholine discs on plasma lipoproteins in humans. Arterioscler Thromb Vasc Biol (1999) 19(4):979-989.
34. Nanjee MN, Cooke CJ, Garvin R, Semeria F, Lewis G, Olszewski WL, Miller NE: Intravenous apoA-I/lecithin discs increase pre-?̂-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res (2001) 42(10):1586-1593.
35. Spieker LE, Sudano I, Hurlimann D, Lerch PG, Lang MG, Binggeli C, Corti R, Ruschitzka F, Luscher TF, Noll G: High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation (2002) 105(12):1399-1402.
36. Bisoendial RJ, Hovingh GK, Levels JH, Lerch PG, Andresen I, Hayden MR, Kastelein JJ, Stroes ES: Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation (2003) 107(23):2944-2948.
37. Carlson LA: Effect of a single infusion of recombinant human proapolipoprotein A-I liposomes (synthetic HDL) on plasma lipoproteins in patients with low high-density-lipoprotein cholesterol. Nutr Metab Cardiovasc Dis (1995) 5:85-91.
38. Eriksson M, Carlson LA, Miettinen TA, Angelin B: Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation (1999) 100(6):594-598.
39. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P et al: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. J Am Med Assoc (2006) 295(13):1556-1565.
40. Nissen SE: Effect of intensive lipid lowering on progression of coronary atherosclerosis: Evidence for an early benefit from the reversal of atherosclerosis with aggressive lipid lowering (REVERSAL) trial. Am J Cardiol (2005) 96(5A):61F-68F.
41. Milano/phospholipid complexes emerging pharmacological strategies and medications for the prevention of atherosclerotic plaque progression. Curr Drug Targets Cardiovasc Haematol Disord (2005) 5(6):471-479.
42. Milano. J Am Coll Cardiol (2006) 47(5):992-997.
43. Remaley AT, Thomas F, Stonik JA, Demosky SJ, Bark SE, Neufeld EB, Bocharov AV, Vishnyakova TG, Patterson AP, Eggerman TL, Santamarina-Fojo S, Brewer HB: Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J Lipid Res (2003) 44(4):828-836.
44. Anantharamaiah G, Navab M, Reddy ST, Garber DW, Datta G, Gupta H, White CR, Handattu SP, Palgunachari MN, Chaddha M, Mishra VK et al: Synthetic peptides: Managing lipid disorders. Curr Opin Lipidol (2006) 17(3):233-237.
45. Navab M, Anantharamaiah GM, Hama S, Garber DW, Chaddha M, Hough G, Lallone R, Fogelman AM: Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation (2002) 105(3):290-292. • This study reports an apoAI mimetic peptide that inhibits aortic lesion development in mouse models of atherosclerosis.
46. Anantharamaiah GM, Jones JL, Brouillette CG, Schmidt CF, Chung BH, Hughes TA, Bhown AS, Segrest JP: Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J Biol Chem (1985) 260(18):10248-10255. • This paper is one of the first reports on apoAI mimetic peptides.
47. Segrest JP, Garber DW, Brouillette CG, Harvey SC, Anantharamaiah GM: The amphipathic α helix: A multifunctional structural motif in plasma apolipoproteins. Adv Protein Chem (1994) 45:303-369.
48. Segrest JP, De Loof H, Dohlman JG, Brouillette CG, Anantharamaiah GM: Amphipathic helix motif: Classes and properties. Proteins (1990) 8(2):103-117. • This is a comprehensive review of amphipathic helices.
49. Datta G, Chaddha M, Hama S, Navab M, Fogelman AM, Garber DW, Mishra VK, Epand RM, Epand RF, Lund-Katz S, Phillips MC et al: Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res (2001) 42(7):1096-1104. • The structural determinants for the function of apoAI mimetic peptide are described.
50. Li X, Chyu KY, Faria Neto JR, Yano J, Nathwani N, Ferreira C, Dimayuga PC, Cercek B, Kaul S, Shah PK: Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation (2004) 110(12):1701- 1705.
51. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Wagner AC, Frank JS, Datta G, Garber D, Fogelman AM: Oral D-4F causes formation of pre-β high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation (2004) 109(25):3215-3220. •• This paper provides a mechanistic explanation of the effects of orally administered D-4F mimetic peptide in a mouse model of atherosclerosis.
52. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR, Yu N, Ansell BJ, Datta G, Garber DW, Fogelman AM: Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol (2005) 25(7):1325- 1331. •• This review summarizes the physicochemical properties of class A amphipathic peptides and correlates this with their biological activity.
53. de la Llera Moya M, Atger V, Paul JL, Fournier N, Moatti N, Giral P, Friday KE, Rothblat G: A cell culture system for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum components and efflux, esterification, and transfer. Arterioscler Thromb (1994) 14(7):1056-1065.
54. Fournier N, de la Llera Moya M, Burkey BF, Swaney JB, Paterniti J Jr, Moatti N, Atger V, Rothblat GH: Role of HDL phospholipid in efflux of cell cholesterol to whole serum: Studies with human apoA-I transgenic rats. J Lipid Res (1996) 37(8):1704-1711.
55. Ou Z, Ou J, Ackerman AW, Oldham KT, Pritchard KA Jr: L-4F, an apolipoprotein A-1 mimetic, restores nitric oxide and superoxide anion balance in low-density lipoprotein-treated endothelial cells. Circulation (2003) 107(11):1520-1524. •• This study reports the effect of the apoAI mimetic peptide with four phenylalanines on endothelial function and vascular reactivity.
56. Ou J, Ou Z, Jones DW, Holzhauer S, Hatoum OA, Ackerman AW, Weihrauch DW, Gutterman DD, Guice K, Oldham KT, Hillery CA, Pritchard KA Jr: L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation (2003) 107(18):2337-2341. •• Using the knowledge that endothelial dysfunction due to reactive oxygen species is involved in sickle cell disease, this study was the first to demonstrate an effect of apoAI mimetic peptides in correcting the endothelial dysfunction in vivo.
57. Ou J, Wang J, Xu H, Ou Z, Sorci-Thomas MG, Jones DW, Signorino P, Densmore JC, Kaul S, Oldham KT, Pritchard KA Jr: Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet. Circ Res (2005) 97(11):1190-1197.
58. Moore RE, Kawashiri MA, Kitajima K, Secreto A, Millar JS, Pratico D, Rader DJ: Apolipoprotein A-I deficiency results in markedly increased atherosclerosis in mice lacking the LDL receptor. Arterioscler Thromb Vasc Biol (2003) 23(10):1914-1920.
59. Nair DT, Kaur KJ, Singh K, Mukherjee P, Rajagopal D, George A, Bal V, Rath S, Rao KV, Salunke DM: Mimicry of native peptide antigens by the corresponding retro-inverso analogs is dependent on their intrinsic structure and interaction propensities. J Immunol (2003) 170(3):1362- 1373.
60. Qin S, Kamanna VS, Liu T, Zhang L, Ganji SH, Lai J, Bachovchin WW, Kashyap ML: Reverse-D4F (Rev-D4F), an apolipoprotein-AI mimetic peptide, inhibits atherosclerosis in apolipoprotein E-null mice. Circulation (2005) 112(Suppl 17):Abs 111.
61. Garber DW, Datta G, Chaddha M, Palgunachari MN, Hama SY, Navab M, Fogelman AM, Segrest JP, Anantharamaiah GM: A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res (2001) 42(4):545-552. •• This is the first in vivo demonstration that a model class A amphipathic helical peptide has anti-atherosclerotic properties.
62. Epand RM, Gawish A, Iqbal M, Gupta KB, Chen CH, Segrest JP, Anantharamaiah GM: Studies of synthetic peptide analogs of the amphipathic helix. Effect of charge distribution, hydrophobicity, and secondary structure on lipid association and lecithin:cholesterol acyltransferase activation. J Biol Chem (1987) 262(19):9389-9396.
63. Remaley AT, Stonik JA, Fairwell T, Demosky SJ, Neufeld EB, Brewer HB: Asymmetry in lipid affinity of multihelical amphipathic peptides: An important structural determinant for specificity of ABCA1-dependent cholesterol efflux by peptides. Circulation (2004) 110(Suppl 17):Abs 243.
64. Remaley AT, Stonik JA, Demosky SJ, Neufeld EB, Bocharov AV, Vishnyakova TG, Eggerman TL, Patterson AP, Duverger NJ, Santamarina-Fojo S, Brewer HB Jr: Apolipoprotein specificity for lipid efflux by the human ABCA1 transporter. Biochem Biophys Res Commun (2001) 280(3):818-823.
65. Gillotte KL, Zaiou M, Lund-Katz S, Anantharamaiah GM, Holvoet P, Dhoest A, Palgunachari MN, Segrest JP, Weisgraber KH, Rothblat GH, Phillips MC: Apolipoprotein-mediated plasma membrane microsolubilization. Role of lipid affinity and membrane penetration in the efflux of cellular cholesterol and phospholipid. J Biol Chem (1999) 274(4):2021-2028.
66. Mishra VK, Palgunachari MN, Datta G, Phillips MC, Lund-Katz S, Adeyeye SO, Segrest JP, Anantharamaiah GM: Studies of synthetic peptides of human apolipoprotein A-I containing tandem amphipathic α-helixes. Biochemistry (1998) 37(28):10313-10324.
67. Palgunachari MN, Mishra VK, Lund-Katz S, Phillips MC, Adeyeye SO, Alluri S, Anantharamaiah GM, Segrest JP: Only the two end helixes of eight tandem amphipathic helical domains of human apo A-I have significant lipid affinity. Implications for HDL assembly. Arterioscler Thromb Vasc Biol (1996) 16(2):328-338.
68. Natarajan P, Forte TM, Chu B, Phillips MC, Oram JF, Bielicki JK: Identification of an apolipoprotein A-I structural element that mediates cellular cholesterol efflux and stabilizes ATP binding cassette transporter A1. J Biol Chem (2004) 279(23):24044-24052.
69. Segrest JP, Jones MK, De Loof H, Brouillette CG, Venkatachalapathi YV, Anantharamaiah GM: The amphipathic helix in the exchangeable apolipoproteins: A review of secondary structure and function. J Lipid Res (1992) 33(2):141-166.
70. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Wagner AC, Hama S, Hough G, Bachini E, Garber DW, Mishra VK, Palgunachari MN, Fogelman AM: An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol (2005) 25(9):1932-1937. • This paper shows that peptides with amphipathic helixes of class G* are also effective in protecting against atherosclerosis in animal models.
71. Uhlar CM, Whitehead AS: Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem (1999) 265(2):501-523.
72. Stonik JA, Remaley AT, Demosky SJ, Neufeld EB, Bocharov A, Brewer HB: Serum amyloid A promotes ABCA1-dependent and ABCA1-independent lipid efflux from cells. Biochem Biophys Res Commun (2004) 321(4):936-941.
73. Kisilevsky R, Tam SP: Macrophage cholesterol efflux and the active domains of serum amyloid A 2.1. J Lipid Res (2003) 44(12):2257-2269.
74. Rudel LL, Lee RG, Cockman TL: Acyl coenzyme A:cholesterol acyltransferase types 1 and 2: Structure and function in atherosclerosis. Curr Opin Lipidol (2001) 12(2):121-127.
75. Tam SP, Ancsin JB, Tan R, Kisilevsky R: Peptides derived from serum amyloid A prevent, and reverse, aortic lipid lesions in apoE-/-mice. J Lipid Res (2005) 46(10):2091-2101.
76. Anantharamaiah GM, Brouillette CG, Engler JA, De Loof H, Venkatachalapathi YV, Boogaerts J, Segrest JP: Role of amphipathic helixes in HDL structure/function. Adv Exp Med Biol (1991) 285:131-140.
77. Gupta H, White CR, Handattu S, Garber DW, Datta G, Chaddha M, Dai L, Gianturco SH, Bradley WA, Anantharamaiah GM: Apolipoprotein E mimetic peptide dramatically lowers plasma cholesterol and restores endothelial function in watanabe heritable hyperlipidemic rabbits. Circulation (2005) 111(23):3112-3118. • This article shows that a synthetic peptide lowers plasma levels of apoB-containing particles and improves the vascular reactivity in an animal model of hypercholesterolemia.
78. Milano apoprotein. Isolation and characterization of a cysteinecontaining variant of the A-I apoprotein from human high density lipoproteins. J Clin Invest (1980) 66(5):901-907.
79. Milano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest (1980) 66(5):892-900.
80. Milano. Atherosclerosis (1997) 128(1):121-128.
81. Milano dimer. Biochemistry (1999) 38(49):16307- 16314.
82. Calabresi L, Tedeschi G, Treu C, Ronchi S, Galbiati D, Airoldi S, Sirtori CR, Marcel Y, Franceschini G: Limited proteolysis of a disulfide-linked apoA-I dimer in reconstituted HDL. J Lipid Res (2001) 42(6):935-942.
83. Milano. Biochem Biophys Res Commun (2002) 297(2):206-213.
84. Paris exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry (2002) 41(6):2089-2096.
85. Nguyen SD, Jeong TS, Sok DE: Apolipoprotein A-I-mimetic peptides with antioxidant actions. Arch Biochem Biophys (2006) 451(1):34-42.
86. Bar-Or D, Rael LT, Lau EP, Rao NK, Thomas GW, Winkler JV, Yukl RL, Kingston RG, Curtis CG: An analog of the human albumin Nterminus (Asp-Ala-His-Lys) prevents formation of copper-induced reactive oxygen species. Biochem Biophys Res Commun (2001) 284(3):856-862.
87. Bar-Or D, Thomas GW, Rael LT, Lau EP, Winkler JV: Asp-Ala-His-Lys (DAHK) inhibits copper-induced oxidative DNA double strand breaks and telomere shortening. Biochem Biophys Res Commun (2001) 282(1):356-360.
88. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Frank JS, Grijalva VR, Ganesh VK, Mishra VK, Palgunachari MN, Fogelman AM: Oral small peptides render HDL antiinflammatory in mice and monkeys and reduce atherosclerosis in ApoE null mice. Circ Res (2005) 97(6):524-532. • This study demonstrated that small peptides can have anti-atherogenic effects in mice.
89. Milano and 1-palmitoyl-2-oleoyl phosphatidylcholine complex (ETC-216) protects the in vivo rabbit heart from regional ischemia-reperfusion injury. J Pharmacol Exp Ther (2004) 311(3):1023-1031.
90. Paterno R, Ruocco A, Postiglione A, Hubsch A, Andresen I, Lang MG: Reconstituted high-density lipoprotein exhibits neuroprotection in two rat models of stroke. Cerebrovasc Dis (2004) 17(2-3):204-211.
91. J-L DASSUEX (Dassuex J-L, Sekul R, Bittner K, Cornut I, Metz G, Dufourcq J): Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders. WO-09916459 (1999).